1887

Abstract

A mAb against the NadA protein from strain 3006 (serosubtype B : 2b : P1.2 : P5.2,8) demonstrated strong bactericidal activity against Brazilian epidemic serogroup B strain N44/89 (B : 4,7 : P1.19,15 : P5.5,7) and a serogroup C strain, IMC 2135 (C : 2a : P1.5,2), but not against another serogroup C strain, N1002/90 (C : 2b : P1.3 : P5.8). The immunogenicity of native NadA in an outer-membrane vesicle (OMV) preparation was also tested. Serum from mice immunized with OMV from serogroup B strain N44/89, which contains the NadA protein, showed bactericidal activity against serogroup B and C strains possessing NadA. In dot-blot analysis of 100 serogroup B and 100 serogroup C isolates from Brazilian patients, the mAb to NadA recognized about 60 % of the samples from both serogroups. The molecular mass of the NadA protein from strain N44/89 determined by mass spectrometry was 37 971 Da and the peptide sequences were identical to those of NadA from strain MC58.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05017-0
2003-02-01
2019-09-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/2/121.html?itemId=/content/journal/jmm/10.1099/jmm.0.05017-0&mimeType=html&fmt=ahah

References

  1. Anderson, E. L., Bowers, T., Mink, C. M., Kennedy, D. J., Belshe, R. B., Harakeh, H., Pais, L., Holder, P. & Carlone, G. M. ( 1994;). Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 62, 3391–3395.
    [Google Scholar]
  2. Blake, M. S. & Gotschlich, E. C. (1986). Functional and immunological properties of pathogenic Neisseria surface proteins. In Bacterial Outer Membranes as Model Systems, pp. 377–400. Edited by M. Inoue. New York: Wiley.
  3. Boslego, J., Garcia, J., Cruz, C. & 11 other authors ( 1995;). Efficacy, safety, and immunogenicity of a meningococcal group B (15 : P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13, 821–829.[CrossRef]
    [Google Scholar]
  4. Comanducci, M., Bambini, S., Brunelli, B. & 12 other authors ( 2002;). NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195, 1445–1454.[CrossRef]
    [Google Scholar]
  5. Frasch, C. E. (1995). Meningococcal vaccines. In Meningococcal Disease, pp. 245–283. Edited by K. Cartwright. New York: Wiley.
  6. Frasch, C. E. & Robbins, J. D. ( 1978;). Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 147, 629–644.[CrossRef]
    [Google Scholar]
  7. Frasch, C. E., Zollinger, W. D. & Poolman, J. T. ( 1985;). Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7, 504–510.[CrossRef]
    [Google Scholar]
  8. Fukasawa, L. O., Gorla, M. C. O., Schenkman, R. P. F., Garcia, L. R., Carneiro, S. M., Raw, I. & Tanizaki, M. M. ( 1999;). Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17, 2951–2958.[CrossRef]
    [Google Scholar]
  9. Fukasawa, L. O., Gorla, M. C. O., Lemos, A. P., Brandileone, M. C., Schenkman, R. P. F., Frasch, C. E., Raw, I. & Tanizaki, M. M. (2000). A 190 kDa conserved surface protein from Neisseria meningitidis that induces bactericidal antibodies. In Abstract Book of the Twelfth International Pathogenic Neisseria Conference, Galveston, TX, USA.
  10. Granoff, D. M., Gupta, R. K., Belshe, R. B. & Anderson, E. L. ( 1998;). Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178, 870–874.[CrossRef]
    [Google Scholar]
  11. Kearney, J. F., Radbruch, A., Liesegang, B. & Rajewsky, K. ( 1979;). A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123, 1548–1550.
    [Google Scholar]
  12. Martin, D., Cadieux, N., Hamel, J. & Brodeur, B. R. ( 1997;). Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185, 1173–1183.[CrossRef]
    [Google Scholar]
  13. Maslanka, S. E., Gheesling, L. L., Libutti, D. E. & 14 other authors ( 1997;). Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4, 156–167.
    [Google Scholar]
  14. Milagres, L. G., Ramos, S. R., Sacchi, C. T., Melles, C. E., Vieira, V. S., Sato, H., Brito, G. S., Moraes, J. C. & Frasch, C. E. ( 1994;). Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62, 4419–4424.
    [Google Scholar]
  15. Pizza, M., Scarlato, V., Masignani, V. & 33 other authors ( 2000;). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820.[CrossRef]
    [Google Scholar]
  16. Poolman, J. T. ( 1995;). Development of a meningococcal vaccine. Infect Agents Dis 4, 13–28.
    [Google Scholar]
  17. Richmond, P., Kaczmarski, E., Borrow, R., Findlow, J., Clark, S., McCann, R., Hill, J., Barker, M. & Miller, E. ( 2000;). Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181, 761–764.[CrossRef]
    [Google Scholar]
  18. Rosenqvist, E., Hoiby, E. A., Wedege, E., Kusecek, E. & Achtman, M. ( 1993;). The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 167, 1065–1073.[CrossRef]
    [Google Scholar]
  19. Sacchi, C. T., Lemos, A. P., Popovic, T. & 8 other authors ( 2001;). Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development. J Clin Microbiol 39, 2897–2903.[CrossRef]
    [Google Scholar]
  20. Shevchenko, A., Chernushevic, I., Shevchenko, A., Wilm, M. & Mann, M. ( 2002;). ‘De novo’ sequencing of peptides recovered from in-gel digested protein by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 20, 107–118.[CrossRef]
    [Google Scholar]
  21. Twumasi, P. A., Jr, Kumah, S., Leach, A. & 9 other authors ( 1995;). A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171, 632–638.[CrossRef]
    [Google Scholar]
  22. Wedege, E. & Froholm, L. O. ( 1986;). Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51, 571–578.
    [Google Scholar]
  23. Wedege, E., Hoiby, E. A., Rosenqvist, E. & Froholm, L. O. ( 1990;). Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol 31, 195–201.[CrossRef]
    [Google Scholar]
  24. Zollinger, W. D. (1997). New and improved vaccines against meningococcal disease. In New Generation Vaccines, pp. 469–488. Edited by M. M. Levine, G. C. Woodrow, J. B. Kaper & G. S. Cobon. New York: Marcel Dekker.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05017-0
Loading
/content/journal/jmm/10.1099/jmm.0.05017-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error